Compare Upstart Holdings Inc (UPST) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Upstart Holdings Inc vs Viatris Inc — how do they compare? Upstart Holdings Inc trades at $29.27 (market cap $2.76B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 7.2× Upstart Holdings Inc's market cap, and Viatris Inc pays a 2.83% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| UPST | VTRS | |
|---|---|---|
Market Cap | $2.76B | $19.79B |
Sector | Financials | Health |
52-Week High | $84.13 | $17.39 |
52-Week Low | $24.22 | $8.74 |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Upstart Holdings (UPST) trades at $29.27, down 0.81% on the day, with a bearish technical signal but improving fundamentals. The company reported a net income of $53.60 million in 2025, marking a significant turnaround from prior losses. Recent news highlights AI-driven lending growth and a $600 million funding deal with Neuberger Berman, though quarterly earnings have been mixed with a recent miss in Q1 2026.
The stock presents a high-risk, high-reward opportunity, supported by analyst consensus targets near $42.00 but challenged by volatile cash flows and rising debt. Key risks include execution on new loan products and macroeconomic sensitivity, while institutional sentiment remains divided with a 45% buy rating. Near-term direction hinges on Q2 2026 results due August 4, 2026.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
